Impel Neuropharma Financing
Impel Neuropharma Inc, Corporation just had published form D about $80,000 debt financing. This is a new filing. Impel Neuropharma was able to finance itself with $80,000. That is 100.00% of the offering. The total financing amount was $80,000. The form was filed on 2016-10-18. The reason for the financing was: unspecified.
Impel Neuropharma is based in Washington. The firm’s business is Other Health Care. The SEC form was signed by John Hoekman President and CEO. The company was incorporated more than five years ago. The filler’s address is: 915 East Pine St, Suite 401, Seattle, Wa, Washington, 98122. John D. Hoekman is the related person in the form and it has address: C/O Impel Neuropharma, Inc., 915 East Pine St., Suite 401, Seattle, Wa, Washington, 98122. Link to Impel Neuropharma Filing: 000116840416000042.
Analysis of Impel Neuropharma Offering
On average, startups in the Other Health Care sector, sell 68.60% of the total offering size. Impel Neuropharma sold 100.00% of the offering. Could this mean that the trust in Impel Neuropharma is high? The average fundraising size for companies in the Other Health Care industry is $1.16 million. The offering was 93.10% smaller than the average of $1.16 million. Of course this should not be interpreted as negative. Businesses raise funds for a variety of needs and reasons. The minimum investment for this fundraising is set at $0. If you know more about the reasons for the fundraising, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Impel Neuropharma Also
The Form D signed by John Hoekman might help Impel Neuropharma Inc’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.